Cargando…

Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production

BACKGROUND: Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected cells and tumor cells without prior sensitization. The human NK-92MI cell line is among the most widely used NK cell in preclinical research studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhl, Christopher, Nyirenda, Themba, Siegel, David S., Lee, Woo Y., Zilberberg, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280577/
https://www.ncbi.nlm.nih.gov/pubmed/35846441
http://dx.doi.org/10.1016/j.heliyon.2022.e09167
_version_ 1784746678901800960
author Uhl, Christopher
Nyirenda, Themba
Siegel, David S.
Lee, Woo Y.
Zilberberg, Jenny
author_facet Uhl, Christopher
Nyirenda, Themba
Siegel, David S.
Lee, Woo Y.
Zilberberg, Jenny
author_sort Uhl, Christopher
collection PubMed
description BACKGROUND: Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected cells and tumor cells without prior sensitization. The human NK-92MI cell line is among the most widely used NK cell in preclinical research studies and has also been approved for clinical applications. Previous studies have shown that osteoblasts (OSB) confer drug resistance in multiple myeloma (MM) and other cancers that metastasize to the bone marrow. AIM: We evaluated here how OSB, which are bone forming cells and a key cellular component of the bone marrow microenvironment, modulate the cytotoxic activity of NK-92MI cells against the MM.1S multiple myeloma cell line. METHODS: The osteoblastic niche was recapitulated with either the osteoblastic cell line hFOB 1.19 (hFOB) or primary osteoblasts (P-OSB) derived from surgical resections. Time-lapse imaging was utilized to quantify changes in MM.1S cell viability under different conditions, including: (1) Co-culture of MM.1S with NK92MI cells, (2) triple-culture of hFOB or P-OSB with MM.1S and NK-92MI, and (3) MM.1S or NK-92MI cells primed with OSB-derived supernatant. Cytokine analysis was conducted to quantify potential secreted factors associated with the protective effects of OSB. RESULTS: The physical presence of OSB hindered the activity of NK-92MI cells, resulting in the increased viability of MM.1S compared to co-cultures which lacked OSB. This observation was accompanied by reduced perforin and granzyme A secretion from NK-92MI cells. Contact of OSB and NK-92MI cells also induced interleukin 6 (IL-6) and interleukin 10 (IL-10) production; two cytokines which are known to impair the NK cell immunity against MM and other cancers. OSB supernatant also conferred cytoprotection to MM.1S, suggesting a dual mechanism by which OSB may modulate both NK and MM cells. CONCLUSIONS: We demonstrated here that OSB can negatively impact the activity of NK cells against MM. As NK cells and their chimeric antigen receptor-modified versions become more widely used in the clinic, our results suggest that understanding the role of OSB as potential immunoregulators of the NK cell-mediated cytotoxic response in the bone marrow tumor microenvironment may provide new opportunities for enhancing the effectiveness of this potent immunotherapeutic approach.
format Online
Article
Text
id pubmed-9280577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92805772022-07-15 Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production Uhl, Christopher Nyirenda, Themba Siegel, David S. Lee, Woo Y. Zilberberg, Jenny Heliyon Research Article BACKGROUND: Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected cells and tumor cells without prior sensitization. The human NK-92MI cell line is among the most widely used NK cell in preclinical research studies and has also been approved for clinical applications. Previous studies have shown that osteoblasts (OSB) confer drug resistance in multiple myeloma (MM) and other cancers that metastasize to the bone marrow. AIM: We evaluated here how OSB, which are bone forming cells and a key cellular component of the bone marrow microenvironment, modulate the cytotoxic activity of NK-92MI cells against the MM.1S multiple myeloma cell line. METHODS: The osteoblastic niche was recapitulated with either the osteoblastic cell line hFOB 1.19 (hFOB) or primary osteoblasts (P-OSB) derived from surgical resections. Time-lapse imaging was utilized to quantify changes in MM.1S cell viability under different conditions, including: (1) Co-culture of MM.1S with NK92MI cells, (2) triple-culture of hFOB or P-OSB with MM.1S and NK-92MI, and (3) MM.1S or NK-92MI cells primed with OSB-derived supernatant. Cytokine analysis was conducted to quantify potential secreted factors associated with the protective effects of OSB. RESULTS: The physical presence of OSB hindered the activity of NK-92MI cells, resulting in the increased viability of MM.1S compared to co-cultures which lacked OSB. This observation was accompanied by reduced perforin and granzyme A secretion from NK-92MI cells. Contact of OSB and NK-92MI cells also induced interleukin 6 (IL-6) and interleukin 10 (IL-10) production; two cytokines which are known to impair the NK cell immunity against MM and other cancers. OSB supernatant also conferred cytoprotection to MM.1S, suggesting a dual mechanism by which OSB may modulate both NK and MM cells. CONCLUSIONS: We demonstrated here that OSB can negatively impact the activity of NK cells against MM. As NK cells and their chimeric antigen receptor-modified versions become more widely used in the clinic, our results suggest that understanding the role of OSB as potential immunoregulators of the NK cell-mediated cytotoxic response in the bone marrow tumor microenvironment may provide new opportunities for enhancing the effectiveness of this potent immunotherapeutic approach. Elsevier 2022-03-24 /pmc/articles/PMC9280577/ /pubmed/35846441 http://dx.doi.org/10.1016/j.heliyon.2022.e09167 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Uhl, Christopher
Nyirenda, Themba
Siegel, David S.
Lee, Woo Y.
Zilberberg, Jenny
Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title_full Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title_fullStr Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title_full_unstemmed Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title_short Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production
title_sort natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced il-6 and il-10 production
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280577/
https://www.ncbi.nlm.nih.gov/pubmed/35846441
http://dx.doi.org/10.1016/j.heliyon.2022.e09167
work_keys_str_mv AT uhlchristopher naturalkillercellsactivityagainstmultiplemyelomacellsismodulatedbyosteoblastinducedil6andil10production
AT nyirendathemba naturalkillercellsactivityagainstmultiplemyelomacellsismodulatedbyosteoblastinducedil6andil10production
AT siegeldavids naturalkillercellsactivityagainstmultiplemyelomacellsismodulatedbyosteoblastinducedil6andil10production
AT leewooy naturalkillercellsactivityagainstmultiplemyelomacellsismodulatedbyosteoblastinducedil6andil10production
AT zilberbergjenny naturalkillercellsactivityagainstmultiplemyelomacellsismodulatedbyosteoblastinducedil6andil10production